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Abstract
Background: Anthracycline based regiments and/or taxanes and adjuvant radiotherapy; the main modalities of treatment for
breast cancers are associated with deterioration of pulmonary functions and progressive pulmonary toxicities. Aim: Assessment
of pulmonary toxicities and impact on pulmonary functions mainly in terms of decline of forced vital capacity (FVC) and the
ratio of forced expiratory volume (FEV) in 1 Second and FEV1/FVC ratio with different treatment times and follow ups in car-
cinoma breast patients receiving anthracycline and/or taxane based chemotherapy and radiotherapy. Materials and methods: A
prospective single institutional cohort study was performed with 58 breast cancer patients between January 2011 to July 2012
who received either anthracycline based (37 patients received 6 cycles FAC= 5 FU, Adriamycin, Cyclophosphamide regime) and
radiotherapy or anthracycline and taxane based chemotherapy (21 patients received 4cycles AC= Adriamycin, Cyclophospha-
mide; followed by 4 cycles of T=Taxane) and radiotherapy. Assessment of pulmonary symptoms and signs, chest x-ray and pul-
monary function tests were performed at baseline, midcycle, at end of chemotherapy, at end radiotherapy, at 1 and 6 months
follow ups and compared. By means of a two-way analysis of variance (ANOVA) model, the course of lung parameters across
the time points was compared. Results and Conclusion: Analysis of mean forced vital capacities at different points of study times
showed definitive declining pattern, which is at statistically significant level at the end of 6 th month of follow up (p=0.032) .The
FEV1/FVC ratio (in percentage) also revealed a definite decreasing pattern over different treatment times and at statistically
significant level at 6th month follow up with p value 0.003. Separate analysis of mean FEV1/FVC ratios over time in anthracy-
cline based chemotherapy and radiotherapy group as well as anthracycline and taxane based chemotherapy and radiotherapy
group showed a similar declining pattern.
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Introduction
Breast cancer is the leading cause of cancer death among
women around the world.1 It accounts for 26% of all malig-
nancies in women and second most common cause of cancer
death in women.2 In India it shows mixed incidence pattern
with breast cancer being second to cancer of the cervix in
rural areas1, 2,; however, in metropolitan cities the incidence
of breast cancer has crossed that of cervix.2 Mathematical
models suggest that both the adoption of screening mam-
mography and the availability of adjuvant chemotherapy,
radiotherapy and tamoxifen have contributed approximately
equally to the improvement of breast cancer outcomes.3
Adjuvant chemotherapy reduces local recurrence after radia-
tion therapy in breast cancer. Anthracycline (doxorubi-
cin)-based regimens (± taxanes for high-risk disease) have
been associated with superior outcomes as compared to
nonanthracycline containing regimens. Recent evidence
suggests that disease free survival (DFS) and overall survival
(OS) of breast cancers has been increased with taxane-based
therapy as compared to anthracycline-based therapy. Neo-
adjuvant chemotherapy is considered standard of care in
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high-risk populations such as young patients and/or ad-
vanced stage disease, and has been evaluated in Stage II–IIIa
breast cancer in randomized trials.3, 4
Paclitaxel (Taxol) is one of the most potent chemotherapeu-
tic agents in the treatment of breast cancers has experienced
widespread use over the past 5 years. . A limited number of
case reports are available concluding that Taxol is associated
with respiratory symptoms, including dyspnea, cough,
wheezing and chest tightness.5 Interstitial and reticulonodu-
lar infiltrates have been described on chest radiographic
examination in few studies with paclitaxel in breast cancers.6
Cases of transient pulmonary infiltrates and suspected inter-
stitial pneumonitis have been reported, although the true
incidence of lung toxicity that is directly related to paclitaxel
is not well understood. A prospective study of lung function
in 33 patients who received paclitaxel with carboplatin (an
agent with little evidence for direct lung toxicity) for
nonthoracic malignancy revealed an isolated decrease in
diffusing capacity without other clinical or radiographic
evidence of pulmonary toxicity .7 Clinicians should be aware
of the potential for paclitaxel to impair pulmonary function.
Randomized trials have found that addition of adjuvant
therapy with taxane to an anthracycline-based chemothera-
py regimen, compared with anthracycline-based chemo-
therapy alone, led to improved survival for high grade breast
cancer patients.8, 9 Irradiation is also an important adjuvant
therapy for breast cancer. Specifically, adjuvant radiation
therapy for selected patients with breast cancer reduces lo-
coregional recurrence and improves overall survival.10, 11
One serious potential risk of radiation therapy for breast
cancer is symptomatic radiation pneumonitis. Fortunately,
with modern irradiation techniques, the risk of radiation
pneumonitis is low (5%), and its course is usually self-limited
.12 However, the risk of radiation pneumonitis has recently
become a greater clinical concern because of reports sug-
gesting that this risk may increase in patients who receive
taxanes.
It is well known that post-operative adjuvant loco-regional
radiotherapy in breast cancer is associated with pulmonary
complications. The frequency and grade of pulmonary com-
plications following radiotherapy for breast cancer are,
however, still debated. Few investigators have quantified this
problem by using objective methods such as pulmonary
function tests (PFTs).13, 14 The PFTs have the advantage of
being widely available and reproducible methods for detect-
ing parenchymal lung damage, if they are performed under
strict standardized conditions.15We performed a prospective
study from January 2011 to August 2012 for pulmonary sta-
tus and  pulmonary toxicities assessment on 58 Breast can-
cer patients attended and registered Radiotherapy depart-
ment of Medical College, Kolkata, who received either an-
thracycline based and/or taxane based chemotherapy fol-
lowed by radiotherapy .The effects of anthracycline and
taxane based chemotherapy and radiotherapy on pulmonary
functions were assessed and variation of pulmonary toxicities
with different treatment times and follow up were analysed.
Methods and Materials
The lung is one of the major dose-limiting organs for radio-
therapy within the thorax. Therefore, the total dose that can
safely be delivered to patients with malignant tumors like
carcinoma breast has to be limited because of the risk of ra-
diation pneumonitis (developing 1 to 6 months after treat-
ment) and radiation fibrosis (developing from 6 months on-
ward). Chemotherapy (regardless of the type of drug) pri-
marily affected the diffusion capacity. So the aim of our
study was to analyze whether and how much the course in
pulmonary function changes over time, forced vital capacity
[FVC], ratio of forced expiratory volume in 1second
[FEV1/FVC ratio] varied between the different treatment
regimens and whether recovery of early pulmonary damage
occurred or not. In general, when chemotherapy and radio-
therapy are combined, two different effects may occur as an
interaction between both modalities, resulting in an en-
hancement of radiation-induced damage or an additional
effect.
Study Area: Department of Radiotherapy, Medical College
and Hospitals, Kolkata.
Study Population: All biopsy proven cases of left sided fe-
male carcinoma breast attending the Radiotherapy Out Pa-
tients’ Department and conforming to inclusion /exclusion
criteria mentioned herein.
Study Period: Case accrual started from January 2011 and it
was divided into preparatory phase, data collection phase
data compilation phase, data analysis phase and preparation
phase.
Sample Size: 60 patients
Sample Design: All the population with carcinoma breast
(female) who conform  to the inclusion / exclusion criteria
mentioned herein and gave consent to be included in the
study.
Inclusion Criteria:
 Female carcinoma breast patients.
 Age above 20 years and below 70 years.
 Those who are eligible to receive anthracycline
and/or taxane based chemotherapy and external
beam radiotherapy.
 Stage II and onwards (American Joint Committee
on Cancer Stage Grouping).
 Karnofsky performance status >70.
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 Baseline normal hematological, renal and hepatic
profile.
 Baseline normal cardiac and pulmonary function
status.
 Informed Consent to participate in this study.
Exclusion Criteria:
 Male carcinoma breast patients.
 Patients undergoing breast conservation surgery.
 Pregnant and lactating patients.
 Any evidence of Metastasis at presentation.
 Previous history of any malignancy.
 Previously received / currently receiving chemo-
therapy / radiotherapy.
 Not enrolled in any other study on Breast cancer.
Study Design: Prospective observational single-Institutional
trial.
Parameters studied
 History.
 Detailed physical examination.
 Pulmonary function test (FEV1, FVC, FEV1/FVC
ratio and VC)
 Chest X Ray (PA and lateral view).
Study Techniques: All biopsy proven cases of left sided car-
cinoma breast attending the OPD of Radiotherapy, Medical
College Hospitals, Kolkata, satisfying the specified Inclusion
and Exclusion Criteria who are willing to participate in the
study were included.
Patients were treated with Anthracycline and / or Taxane
based chemotherapy in the Neo-Adjuvant or Adjuvant set-
ting in combination with Modified Radical Mastectomy
(Timing of surgery depending on operability). In addition all
patients will receive adjuvant External Beam Radiotherapy
(Dose, Portals etc depending on stage and tumour features).
Hormone receptor positive patients will receive adjuvant
Endocrine therapy for a minimum duration of five years.
All patients were subjected to chest X-ray and Pulmonary
function tests (Clinical assessment, Chest X ray, FEV1, FVC,
FEV1/FVC) at baseline, during and at the end of chemo-
therapy, at the end of radiation and during first month and
sixth month follow up.Mid cycle chemotherapy means after
completion of 3rd cycle of chemotherapy in FAC group and
after completion of 4th cycle of chemotherapy in Anthracy-
cline, Cyclophosphamide (AC) followed by Taxane (T
group).
Statistical analysis:
Quantitative variables were compared between two groups
using an unpaired t test for normally distributed variables or
Wilcoxon two sample tests for skewed distributed variables.
Normally distributed variables are reported as mean, stand-
ard deviation, and variance. Skewed distributed variables are
reported as median and range (minimum to maximum).
By means of a two-way ANOVA model, the course of lung
parameters (decline of pulmonary function tests) across the
time points was compared between patients. Correlations
between variables were calculated using Pearson’s or Spear-
man correlation coefficient test as appropriate. All P values
were two-sided and P <0.05 was considered statistically sig-
nificant. Medcalc and Vassarstats were used to perform the
statistical analysis.
Results
Case Accrual
Initially, 60 patients were selected for accrual. Of these, after
careful scrutiny towards meeting of inclusion and exclusion
criteria, 58 breast cancer patients were actually found suita-
ble. All patients under study had left sided breast cancer.
However, 4 patients were expired during and at the end of
chemotherapy and were consequently excluded from the
study. Ultimately 54 patients underwent the study till end.
Baseline Patient Characteristics
TABLE 1: Baseline age distribution of the study population
Age Groups No of Patients Percentage (%)
20-32 years 9 15.52
33-45 years 18 31.03
46-58 years 23 39.65
>58 years 8 13.79
The baseline age distributions of patients under are depicted
in Table 1. The Mean age is 51.5 yrs. Inclusion criteria of our
study was lump size more than 5cm and / or node positive
disease. All N0 patients must have T3 (tumour>5cm) accord-
ing to our study inclusion criteria otherwise node positive.
All the patients in the study population received anthracy-
cline and/or taxane based chemotherapy and post chemo-
therapy radiation of chest flap alone or in combination with
supraclavicular field radiotherapy or chest
flap+supraclavicular field +axillary field radiation. All pa-
tients have undergone mastectomy as the very first treat-
ment or initially received 2-3 cycles of neoadjuvant chemo-
therapy, downstaged and then undergone mastectomy; after
that completed chemotherapy. After completion of chemo-
therapy they received radiation .At the end of chemotherapy
the study population came down to 54.Two patients died
after 4 cycles,1 patient after 5th cycle of chemotherapy and 1
patient after 2nd cycle of chemotherapy. So, 54 patients have
undergone radiotherapy.
Among the 58 patients, 37 patients (63.79%) received only
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anthracycline based (doxorubicin) chemotherapy and 21
patients (36.2%) received both anthracycline and taxane
both based chemotherapy. Moreover, majority of the pa-
tients belonged to poor socio-economic status; received dox-
orubicin, which is supplied free of cost from government
fund in our ward. So we have chosen doxorubicin not epiru-
bicin as anthracycline regime. For those 37 patients who
received only anthracycline based chemotherapy, the regime
chosen was 6cycles of FAC every 21days(Inj 5FU 500mg/m2
iv D1;Inj Doxorubicin 50mg/m2 iv D1; Inj Cyclophospha-
mide 500mg/m2 iv D1).Rest 21 patients received both an-
thracycline and taxane based chemotherapy with 4 cycles of
AC followed by 4 cycles of T(Inj Doxorubicin 60mg/m2 iv
D1,Inj Cyclophosphamide 600mg/m2 iv D1 every 21 days 4
cycles followed by Paclitaxel 175 mg/m2 iv D1 every 21days
4 cycles. Among 58 patients, 42 patients received neoadju-
vant chemotherapy 2-3 cycles, thereafter achieved complete
or partial response, undergone MRM and axillary clearance,
thereafter completed remaining cycles of chemotherapy.
Remaining 16 patients have undergone MRM with axillary
clearance first, thereafter received adjuvant chemothera-
py.54 patients have undergone radiotherapy after completion
of chemotherapy.
Evaluation of pulmonary toxicities following chemo-
therapy and radiotherapy in breast cancer patients
The baseline pulmonary function tests and chest x-ray in-
cluding clinical features were within normal limits in all
patients of the study population.
Assessment of respiratory symptoms: Cough and respiratory
distress were considered as respiratory symptoms.
a) Respiratory distress: Total seven patients, three in the
anthracycline based CT+RTgroup (one during third cycle of
chemotherapy, two during first cycle of chemotherapy)
complained of respiratory distress. Two patients in the an-
thracycline and taxane based CT+RT group developed res-
piratory distress during first cycle of chemotherapy; two
patients during radiotherapy.1 patient during 1month follow
up and 3 patients in 6th month of follow up complained of
moderate respiratory distress. From symptoms only we
couldn’t distinguish that whether the distress was due to
cardiological or pulmonary damage .Patients were urgently
sent for immediate cardiological evaluation -and chest x-ray.
None revealed any significant cardiological abnormality. The
patient who developed respiratory distress during 1 month
follow up revealed bilateral lung metastasis in chest x-ray
and among those 3 who developed distress at 6th month
follow up; 1 revealed lung metastasis and 2 showed overt
features of radiation pneumonitis in chest x-ray. So, only 2
patients (3.44%) of the entire study group revealed radiation
pneumonitis at 6th month of follow up.
b) Cough: Total 9 patients in the entire study group devel-
oped cough. Two during 3rd cycle chemotherapy, three dur-
ing 1 month follow up and four during 6th month of follow
ups. Investigations revealed lung metastasis in total 2 pa-
tients and 2 patients developed radiation pneumonitis.
Evaluation of respiratory signs: None of the patients revealed
any overt respiratory signs.
Evaluation of pulmonary toxicities by study tools: All the
patients have undergone chest x ray and pulmonary function
tests(FVC and FEV1/FVC ratio) at baseline ,at mid cycle
chemotherapy, at the end of chemotherapy,at completion of
radiotherapy, at 1moth and 6th month of follow ups.
Interpretation of chest x-ray: Two patients in the entire
study group revealed features of lung metastases in chest
x-ray, one at 1st month of follow up and one at 6th month of
follow up. Only 2 patients (3.44%) in the entire study group
developed features of radiation pneumonitis on chest x-ray
at 6th month of follow up. Both the patients received an-
thracycline and taxane based chemotherapy and radiothera-
py.
Interpretation of pulmonary function tests:
TABLE 2: Variation of mean FEV1/FVC ratios (%) at different points
of time and follow ups.
Mean Median SD Variance
(SD)
Population
(SD)
Baseline
FEV1/FVC
(N=58)
79.17
(0.791)
78.9
(0.789)
9.24 10.05 1.14
Mid cycle CT
FEV1/FVC
(N=58)
78.19
(0.781)
77.9
(0.779)
6.87 5.82 1.38
End CT
FEV1/FVC
N=54)
76.15
(0.761)
75.2
(0.752)
1.94 3.78 1.96
End RT
FEV1/FVC
(N=54)
74.24
(0.742)
74.56
(0.745)
2.32 5.4 2.3
1 month FU
FEV1/FVC
(N=52)
72.59
(0.725)
72.2
(0.722)
2.45 6.7 2.42
6 months FU
FEV1/FVC
(N=50)
69.52
(0.695)
69.075
(0.69)
2.74 74 7.20
Analysis of mean forced vital capacities at different points of
study time (baseline, mid cycle chemotherapy, end of chem-
otherapy, end of radiotherapy, 1 month and 6 months follow
ups showed definitive declining pattern, which is at statisti-
cally significant level at the end of 6 th month of follow up
(p=0.032) in the entire study population (Table 2, Table 3,
and Figure 1).
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TABLE 3: Variation of means of FVCs (forced vitals capacities in liters) over different treatment times:
Mean FVCs P-value
Baseline 2.84 --
MID CT 2.69 0.99
END CT 2.54 0.867
END RT 2.19 0.740
1month follow up 2.06 0.632
6 month follow up 1.81 0.032
P values were compared to baseline; P < 0.05 "means statistically significant"
TABLE 4: Comparison of mean FEV1/FVC ratios with baseline at different times of study time
Different points of study time P-value
Baseline and mid cycle chemotherapy 0.98
Baseline and end of chemotherapy 0.76
Baseline and end of radiotherapy 0.71
Baseline and 1 month follow up 0.068
Baseline and 6 months follow up 0.003
P values of mean FEV1/FVC ratio as compared to baseline; P < 0.05 "means statistically significant"
TABLE 5: Variation of mean FEV1/FVC ratios (%) s at different points of time and follow up period in anthracycline based chemotherapy and
radiotherapy group
Mean Median SD Variance
(SD)
Population
(SD)
Baseline FEV1/FVC
(N=37)
79.82(0.798) 79.2(0.792) 1.32 1.75 1.3
Mid cycle CT FEV1/FVC
(N=37)
78.36(0.736) 77.8(0.778) 1.97 2.1 1.48
End CT FEV1/FVC
(N=34)
76.59(0.765) 76.5(0.765) 2.06 4.02 1.97
End RT FEV1/FVC
(N=34)
75.05(0.75) 75.45(0.754) 2.23 5.01 2.02
1 month FU FEV1/FVC
(N=33)
73.45(0.734) 73.5(0.735) 2.4 5.77 2.36
6 months FU FEV1/FVC
(N=31)
69.9(0.699) 69.5(0.695) 3.2 10.24 3.14
Abbreviations: CT = Chemotherapy; FU = Follow up
TABLE 6: Variation of mean FEV1/FVC ratios with baseline at different times of study time of the study group received anthracycline+ taxane
based CT+RT group
Mean Median SD Variance
(SD)
Population
(SD)
Baseline FEV1/FVC
(N=21)
78.92
(0.789)
78.7
(0.787)
3.46 8.48 6.45
Mid cycle CT FEV1/FVC
(N=21)
77.86
(0.778)
77.6
(O.776)
1.93 6.7 5.98
End CT FEV1/FVC
(N=20)
75.4
(0.754)
75.2
(0.752)
1.61 2.61 1.57
End RT FEV1/FVC
(N=20)
72.85
(O.728)
72.5
(0.725)
1.78 3.17 1.73
1 month FU FEV1/FVC
(N=19)
71.09
(0.719)
72.01
(0.721)
1.74 3.03 1.69
6 months FU
FEV1/FVC(N=19)
68.79
(0.687)
68.45
(0.684)
1.6 2.56 1.55
Abbreviations: CT = Chemotherapy; FU = Follow up; RT = Radiation therapy
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FIG. 1: Graphical representation of variations of mean forced vital capacities (FVC) over different treatment times and follow ups
Y –axis represents Mean FVC s over time
Abbreviations: CT = Chemotherapy, RT= Radiotherapy, FU= Follow up, FAC=5 Fluorouracil, Adriamycin, Cyclophosthamide, AC= Adriamycin,
Cyclophosphamide, T = Taxane
FIG. 2: Graphical representation of pattern of decline of FEV1/FVC ratio in the entire study group.
Y –axis represents FEV1/FVC ratios
Abbreviations: CT = Chemotherapy, RT= Radiotherapy, FU= Follow up, FAC=5 Fluorouracil, Adriamycin, Cyclophosthamide, AC= Adriamycin,
Cyclophosphamide, T = Taxane
TABLE 7: Comparison of mean FEV1/FVC ratios (%) at different points of time and follow up period in the anthracycline based CT+RT group
Different points of study time P values of mean FEV1/FVC ratio as compared with baseline
Anthracycline based CT+RT A+T based CT+RT
Baseline and mid cycle chemotherapy 0.97 0.89
Baseline and end of chemotherapy 0.78 0.72
Baseline and end of radiotherapy 0.73 0.69
Baseline and 1 month follow up 0.087 0.08
Baseline and 6 months follow up 0.02 0.001
P < 0.05 "means statistically significant"
The FEV1/FVC ratio(in percentage) also revealed a definite
decreasing pattern over different treatment time in the en-
tire study group as evidenced from Table 4 and Figure
2,which declines at statistically significant level as compared
to baseline at 6th month follow up with p value 0.003 (Table
4). Separate analysis of mean FEV1/FVC ratios over time in
anthracycline based chemotherapy and radiotherapy group
(Table 5) as well as anthracycline and taxane based chemo-
therapy and radiotherapy group (Table 6) showed a similar
declining pattern, which are statistically significant at 6
months follow up as compared to baseline in both the groups
with p values 0.02 and 0.001 respectively (Table 7).
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Discussion
Regarding pulmonary toxicities following treatment with
chemotherapy and adjuvant radiotherapy in breast cancer
patients several studies showed definitive influence of treat-
ment on pulmonary function tests.
Tse-Kuan Yu et al.16 in a phase 3 randomized study have
shown that Patients with breast cancer treated with sequen-
tial paclitaxel, FAC, and radiation therapy appeared to have a
very low rate of clinically relevant radiation pneumonitis
that was no different from that of patients treated with FAC
alone. But there was significant decrease in DLCO (diffusion
capacity of lung for carbon monoxide) at long term (1 year)
follow up.
Another study12 have demonstrated that loco-regional radi-
otherapy in breast cancer results in reductions of DLCO, VC,
FEV1 and RV. The slight reduction of FEV1 was completely
explained by the decrease in VC, as the relation between
FEV1 and VC was unchanged. Thus, no sign of obstructive
disease was found. We suggest that the reduction of VC re-
flects decreased parenchymal elasticity in the irradiated part
of the lung. The somewhat larger decrease in DLCO may also
indicate an inflammatory reaction in the interstitial tissues.
In 1992, Marks et al.17 reported severe pulmonary complica-
tions in 10% of the patients receiving loco-regional radio-
therapy following high-dose chemotherapy (including car-
mustine) resulting in premature discontinuation of their
radiotherapy. Dose-intensified chemotherapy (FEC-based)
and loco-regional radiotherapy were not associated with
increased pulmonary toxicity in our material and no course
of radiotherapy treatment was prematurely discontinued.
Gage et al.18 have reported similar results to ours using the
CTC high-dose chemotherapy. Thus, the results of Marks et
al.17 may have been influenced by delayed car-
mustine-induced pulmonary toxicity.
In our study, the breast cancer patients received either 6
cycles of FAC chemotherapy followed by adjuvant radio-
therapy or 4 cycles of AC followed by taxane and adjuvant
radiotherapy. Among total 58 study population only 2 pa-
tients developed overt radiological feature of radiation
pneumonitis at 6 months follow up, definitive deterioration
of pulmonary function tests were observed. Both the FVC
(Forced vital capacity) and FEV1/FVC ratio have shown de-
finitive declining trend with chemotherapy and radiotherapy
and mean of those decreased to statistically significant level
at 6th month of follow up. FEV1/FVC ratio decreased below
70% in about 67% patients at 6 months follow up. Separate
analysis of PFTs in two different chemotherapy groups has
shown similar changes.
Breast cancer treated with taxane and anthracycline-based
chemotherapy regimens followed by radiation though did
not develop overt radiation pneumonitis at significant levels,
but declining trends of PFTs warn to continuously monitor
those at different treatment times and follow ups. Before
starting chemotherapy and radiation the baseline PFT must
be within normal limit. Because both of these treatments
have the potential to increase survival in properly selected
patients, our data provide evidence that both treatments can
be given sequentially without a concern for potential inter-
actions that could result in a very serious pulmonary com-
plication, but they result in definitive pulmonary damage.
Conclusion
The conclusion of our study was following anthracycline
and/ taxane based chemotherapy and radiotherapy the breast
cancer patients have shown definitive decrease in forced
vital capacities and FEV1/FVC ratios. The declines were sta-
tistically significant at 6th month of follow up.FEV1/FVC
ratio decreased below 70 % in about 67% of patients at 6
months of follow up.
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